



KMS MEDISURGI LIMITED

CIN L51397MH1999PLC119118

Plot no. 297-301, May Building, Gr. Floor Marine lines (EAST), Princess Street Mumbai Ci
MH-400002 IN Ph-022-66107700/22, 022-67498822, Facsimile: +91-22-22061111,
Website:-www.kmsgroup.in, E-mail id: info@kmsgroup.in

13th November, 2020

To,
BSE limited
Phiroze Jeejeebhoy towers,
Dalal Street,
Mumbai 400001

Sub: Submission of Statement of Standalone Unaudited Financial Result for the half year ended 30.09.2020

Ref: KMS Medisurgi limited (scrip code- 540468)

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we forward herewith Standalone unaudited financial results for the half year ended 30th September, 2020 approved by the Board of Directors of the company at their meeting held on today, the 13th, November, 2020, as recommended by Audit Committee along with the Limited Review report.

The meeting commenced at 03.00 pm. and concluded at 04.30 p.m.

You are requested to please take the above on your record.

Thanking you,

For KMS MEDISURGI LIMITED

FOR KMS MEDISURGI LIMITED

MANAGING DIRECTOR

GAURANG KANAKIA
Managing Director
Din: 00346180



KALPESH JAIN AND ASSOCIATES

CHARTERED ACCOUNTANTS

204, Shamaldas Gandhi Marg., Room No. 5d, Prabhat Co-op. Soc. Ltd.,
Princess Street, Next to Geeta Bhavan Hotel, Mumbai - 400 002.
Tel. No. 022 22090367, + 91 9820559914 | Email Id :-kjainassociates@gmail.com

LIMITED REVIEW REPORT

To
**The Board of Directors of
KMS MEDISURGI LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMS Medisurgi Limited** for six months ended 30th September 2020 ("the statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. . Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of person responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No CIR/CFD/FAC/62/2016 dated 5 July 2016 including manner in which it is to be disclosed, or that it contains any material misstatement.

For **Kalpesh Jain & Associates.**
Chartered Accountants
Firm's Registration No : 132603W



A handwritten signature in blue ink, appearing to read "Kalpesh Jain", with a long horizontal stroke extending to the right.

Kalpesh Jain
Partner

Place : Mumbai
Date : 13th November 2020

M. No. 140164

UDIN : 20140164AAAADA3195

KMS MEDISURGI LIMITED						
CIN NO: L51397MH1999PLC119118						
297/301 May Building, Gr. Floor Marine lines(East) Princess Street Mumbai City MH 400002 IN						
Email Id:Info@kmsgroup.in Tel No: 022-66107722						
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2020						
(Rs. In Lakhs)						
Sr.No	Particulars	Six Month Ended	Preceding 6 Months Ended	Corresponding 6 Months Ended	Year Ended	Year Ended
		30.09.2020	31.03.2020	30.09.2019	31.03.2020	31.03.2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
	Income					
I	Revenue from operations	276.40	520.49	513.92	1,034.41	985.69
II.	Other Income	0.04	(0.33)	0.01	(0.32)	42.09
III.	Total Income (I + II)	276.44	520.16	513.93	1,034.09	1,027.78
IV	Expenses:					
	Cost of materials consumed	222.21	434.04	358.79	792.83	802.23
	Change in Inventories of Stock in Trade	(8.39)	(44.54)	44.54	-	-
	Employee benefits expense	23.60	46.72	29.17	75.89	82.44
	Finance costs	1.22	4.91	2.19	7.10	9.10
	Depreciation and amortization expense	15.60	20.49	20.03	40.52	42.68
	Other expenses	13.15	46.89	52.61	99.50	70.62
	Total expenses	267.39	508.51	507.33	1,015.84	1,007.07
V.	Profit before exceptional and extraordinary items and tax (III-IV)	9.05	11.65	6.60	18.25	20.71
VI.	Exceptional items	-	-	-	-	-
VII.	Profit before extraordinary items and tax (V - VI)	9.05	11.65	6.60	18.25	20.71
VIII.	Extraordinary Items	-	-	-	-	-
IX.	Profit before tax (VII- VIII)	9.05	11.65	6.60	18.25	20.71
X	Tax expense:					
	(1) Current tax	-	7.00	-	7.00	8.37
	(2) Current tax relating to prior years	-	-	-	-	-
	(3) Deferred tax Asset / Liability	-	-	-	-	-
XI	Profit (Loss) for the period (IX-X)	9.05	4.65	6.60	11.25	12.34
XII	Other comprehensive Income	-	-	-	-	-
	a) Items not to be reclassified subsequently to profit or loss valuation	-	-	-	-	-
	Income tax effect on above	-	-	-	-	-
	b) Items to be reclassified subsequently to profit or loss other comprehensive income for the period, net of tax	-	-	-	-	-
XIII	Total Comprehensive income for the period net of tax (XI+XII)	-	-	-	-	-
XIV	Paid-up Equity Share Capital (Face Value of Rs. 10 per Share)	330.00	330.00	330.00	330.00	330.00
XV	Earnings per equity share: of Rs. 10 Each (Not Annualised)					
	(a) Basic	0.27	0.14	0.20	0.34	0.37
	(b) Diluted	0.27	0.14	0.20	0.34	0.37

Notes:

- The Company's Standalone financial results for the Half year ended September 30, 2020 have been reviewed by the Audit Committee and subsequently approved & taken on record by the Board of Directors of the Company at its meeting held on 13th November, 2020.
- Figures of previous reporting periods have been regrouped/reclassified wherever necessary to correspond with the figures of the current reporting period.
- Pursuant to insertion of new clause under Regulation 33, sub-regulation (3), the Company has prepared statement of cash flows for the half year ended September 30, 2020.
- The above results are also available on our website www.kmsgroup.in and the stock exchange's website www.bseindia.com
- Preceding six months figures as at 31.03.2020 is a balancing figure between the annual audited figures as on 31.03.2020 and unaudited six months figures as on 30.09.2019.
- The company is operating in only one segment accordingly no separate reporting is required.
- The Company has not adopted the Indian Accounting Standards (IND AS) in terms of exemption available to companies listed on SME Platform

For and on behalf of the Board of Directors of KMS Medisurgi Ltd
FOR KMS MEDISURGI LIMITED

Gaurang Kanakia
 Managing Director
 DIN No. 00346180

MANAGING DIRECTOR

Place : Mumbai
 Date: 13.11.2020

KMS MEDISURGI LIMITED				
CIN NO: L51397MH1999PLC119118				
297/301 May Building, Gr. Floor Marine lines(East) Princess Street Mumbai Mumbai City MH 400002 IN				
Email Id:Info@kmsgroup.in Tel No: 022-66107722				
UNAUDITED STANDALONE BALANCE SHEET AS AT 30TH SEPTEMBER 2020				
Particulars	Note No.	As on 30th September 2020		As on 31ST MARCH 2020
		Unaudited		Audited
		Rs in lacs		Rs in lacs
I. EQUITY AND LIABILITIES				
1 Shareholders' funds				
(a) Share capital		330.00		330.00
(b) Reserves and surplus		311.79		304.72
		641.79		634.72
2 Non-current liabilities				
(a) Long-term borrowings		106.64		110.58
(b) Long-term provisions				
3 Current liabilities				
(a) Short-term borrowings				
(b) Trade payables		123.12		153.47
(c) Other current liabilities		4.86		10.01
(d) Short tem Provisions		1.98		1.99
TOTAL		878.39		910.78
II. ASSETS				
Non-current assets				
1 (a) Fixed assets				
(i) Tangible assets		167.58		181.41
(ii) Intangible assets				
(b) Non-current investments		0.16		0.16
(c) Deferred Tax asset				
(d) Long-term loans and advances				
(e) Long Term Trade Receivables				
2 Current assets				
(a) Inventories		96.39		135.03
(b) Trade receivables		540.73		549.62
(c) Cash and cash equivalents		56.34		29.15
(d) Short-term loans and advances		17.10		15.32
(e) Other Current Assets		0.09		0.09
TOTAL		878.39		910.78

For and on behalf of the Board of Directors of KMS Medisurgi Ltd

FOR KMS MEDISURGI LIMITED



MANAGING DIRECTOR

Gaurang Kanakia
Managing Director
DIN No. 00346180

Place : Mumbai
Date: 13.11.2020

Unaudited Standalone Cash Flow Statement for the Half year ended 30th September 2020

Rs. In Lakhs

		Period ended September 30,2020		Period ended March 31,2020	
A	CASH FLOW FROM OPERATING ACTIVITIES				
	Profit for the year		9.06		11.24
	Adjustments for :				
	Depreciation	15.60		40.52	
	Interest paid	0.51		1.68	
	Interest received	(0.05)		(2.62)	
			16.06		39.58
	Operating Profit before Working Capital Changes		25.12		50.82
	Adjustments for :				
	Increase / (Decrease) in Trade payables	(30.34)		(141.34)	
	Increase / (Decrease) in Other Current Liabilities	(5.15)		2.47	
	Increase / (Decrease) in Short Term Provisions	-		(11.14)	
	(Increase) / Decrease in Inventories	38.63		45.97	
	(Increase) / Decrease in Other Current Assets	-		0.55	
	(Increase) / Decrease in Short Term Loans & Advances	0.22		12.65	
	(Increase) / Decrease in Trade & Other receivables	8.88	12.24	(44.54)	(135.37)
	Cash Generated from Operations		37.36		(84.55)
	Direct taxes paid		(2.00)		0.98
	Net Cash from Operating Activities	[A]	35.36	[A]	(83.57)
B	CASH FLOW FROM INVESTMENT ACTIVITIES				
	Purchase of Assets		(1.76)		(1.58)
	Sales of Assets				
	Sales / (Purchases) of Investments				
	Interest received		0.04		2.62
	Dividend received				
	Net Cash from Investing Activities	[B]	(1.72)	[B]	1.04
C	CASH FLOW FROM FINANCING ACTIVITIES				
	Proceeds from borrowings		(3.94)		(2.18)
	Repayment of borrowings				
	Increase in Share Capital				
	Increase in Share Premium				
	Interest Expenses		(0.51)		(1.68)
	Dividend On Equity Shares		(1.65)		(1.65)
	Dividend Distribution Tax		(0.34)		(0.34)
	Net Cash Flow from Financial Activities	[C]	(6.44)	[C]	(5.85)
	Net Cash increase/(Decrease) in cash and Cash equivalents	(A+B+C)	27.20	(A+B+C)	(88.38)
	Cash and Cash Equivalents (Opening) :				
	Cash on Hand	0.78		4.43	
	Balance with Banks	28.36	29.15	113.10	117.53
	Cash and Cash Equivalents (Closing) :				
	Cash on Hand	0.90		0.78	
	Balance with Banks	55.45	56.35	28.36	29.15

Notes 1 The above Cash Flow Statement has been prepared under the Indirect Method as set out in the Accounting Standard - 3 (AS3) 'Cash Flow Statement' issued by the Institute of Chartered Accountant of India.

Notes 2 Previous year's figures have been regrouped or rearranged wherever necessary.

For and on behalf of the Board of Directors of KMS Medisurgi Ltd
FOR KMS MEDISURGI LIMITED


MANAGING DIRECTOR

Gaurang Kanakia
Managing Director
DIN No. 00346180

Place : Mumbai
Date: 13.11.2020